Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

GlobeNewswire January 9, 2020

Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors

GlobeNewswire January 8, 2020

Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)

Business Wire November 27, 2019

Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)

Business Wire November 21, 2019

Aclaris Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 12, 2019

Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs

GlobeNewswire November 7, 2019

Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019

GlobeNewswire October 31, 2019

Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)

GlobeNewswire October 24, 2019

Aclaris Therapeutics Announces Divestiture of RHOFADE®

GlobeNewswire October 10, 2019

Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%

GlobeNewswire October 8, 2019

Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm

GlobeNewswire October 6, 2019

FINAL DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 30, 2019

FINAL SEPT. 30 DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - ACRS

GlobeNewswire September 30, 2019

DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 28, 2019

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm

Business Wire September 28, 2019

FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 27, 2019

Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC

GlobeNewswire September 27, 2019

DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire September 27, 2019

Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC

ACCESSWIRE IA September 27, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS

Canada NewsWire September 26, 2019